| Literature DB >> 25858563 |
Gaëtan Prévost1, Lydie Jeandel2, Arnaud Arabo3, Moïse Coëffier4, Mariama El Ouahli5, Marie Picot2, David Alexandre2, Françoise Gobet6, Jérôme Leprince2, Hind Berrahmoune7, Pierre Déchelotte4, Maria Malagon8, Caroline Bonner9, Julie Kerr-Conte9, Fatiha Chigr10, Hervé Lefebvre1, Youssef Anouar2, Nicolas Chartrel11.
Abstract
26RFa is a hypothalamic neuropeptide that promotes food intake. 26RFa is upregulated in obese animal models, and its orexigenic activity is accentuated in rodents fed a high-fat diet, suggesting that this neuropeptide might play a role in the development and maintenance of the obese status. As obesity is frequently associated with type 2 diabetes, we investigated whether 26RFa may be involved in the regulation of glucose homeostasis. In the current study, we show a moderate positive correlation between plasma 26RFa levels and plasma insulin in patients with diabetes. Plasma 26RFa concentration also increases in response to an oral glucose tolerance test. In addition, we found that 26RFa and its receptor GPR103 are present in human pancreatic β-cells as well as in the gut. In mice, 26RFa attenuates the hyperglycemia induced by a glucose load, potentiates insulin sensitivity, and increases plasma insulin concentrations. Consistent with these data, 26RFa stimulates insulin production by MIN6 insulinoma cells. Finally, we show, using in vivo and in vitro approaches, that a glucose load induces a massive secretion of 26RFa by the small intestine. Altogether, the present data indicate that 26RFa acts as an incretin to regulate glucose homeostasis.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25858563 DOI: 10.2337/db14-1864
Source DB: PubMed Journal: Diabetes ISSN: 0012-1797 Impact factor: 9.461